BUDIPINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H27N
Molecular Weight	293.4458
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)N1CCC(CC1)(C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=QIHLUZAFSSMXHQ-UHFFFAOYSA-N

InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C21H27N
Molecular Weight	293.4458
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904 | DOI 10.1007/978-3-7091-6360-3 , Przuntek H., Müller T., 'Diagnosis and Treatment of Parkinson’s Disease - State of the Art' (2013), p. 88, Retrieved from https://books.google.com/books?id=G6DzCAAAQBAJ&dq

Budipine is an antiparkinsonian drug, which was developed by Byk Gulden (now Takeda) for the treatment of Parkinson's disease. The drug has multiple mechanisms of action: it was found to interfere with dopamine biosynthesis, mainly by inhibiting MAO-B enzyme and stimulating aromatic L-amino acid decarboxylase. Also the drug inhibits the dopamine re-uptake and has weak affinity to NMDA and muscarinic receptors. Budipine passes the blood-brain barrier, is metabolized by hydroxylation, and is excreted by both in urine and feces within 24 h.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Amine oxidase [flavin-containing] B 11 Target ID: P27338 Gene ID: 4129.0 Gene Symbol: MAOB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904	Inhibitor 8504	5.0 µM [IC50]
Sodium-dependent dopamine transporter 43 Target ID: Q01959 Gene ID: 6531.0 Gene Symbol: SLC6A3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904	Blocker 555	11.0 µM [IC50]
Aromatic-L-amino-acid decarboxylase 5 Target ID: P20711 Gene ID: 1644.0 Gene Symbol: DDC Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10370904	Activator 1447

Conditions

Condition	Modality	Targets	Highest Phase	Product
Parkinson's disease 232 Sources: https://www.medikamente-per-klick.de/images/ecommerce/08/44/08449633_2011-04_de_o.pdf	Primary		Approved 8583	PARKINSAN Approved Use For combination therapy of Parkinson's disease. Launch Date 1996

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% REVIEW https://pubmed.ncbi.nlm.nih.gov/16784759/			BUDIPINE plasma	Homo sapiens

Doses

Dose	Population	Adverse events
20 mg 3 times / day steady-state, oral Studied dose Dose: 20 mg, 3 times / day Route: oral Route: steady-state Dose: 20 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3302121/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3302121/	Disc. AE: mental confusion... AEs leading to discontinuation/dose reduction: mental confusion (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/3302121/

AEs

AE	Significance	Dose	Population
mental confusion	2 patients Disc. AE	20 mg 3 times / day steady-state, oral Studied dose Dose: 20 mg, 3 times / day Route: oral Route: steady-state Dose: 20 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3302121/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/3302121/

PubMed

Title	Date	PubMed
[On the role of MAO B inhibitors and NMDA antagonists in the therapy of Parkinson's disease].	2010-03	20195940
A new strategy for antidepressant prescription.	2010	21151361
Paradoxical aspects of parkinsonian tremor.	2008-01-30	17973325
Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats.	2006-10-30	16996043
Budipine in Parkinson's tremor.	2006-10-25	16784759
[Diagnosis and therapy of idiopathic Parkinson's disease].	2006-05-15	20104716
Efficacy and safety of high-dose cabergoline in Parkinson's disease.	2006-01	16367894
Pharmacotherapy of Parkinson's disease in Germany.	2005-08	15765268
Efficacy of budipine and placebo in untreated patients with Parkinson's disease.	2005-08	15583956
Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats.	2005-07	15834446
The anti-Parkinson drug budipine is exported actively out of the brain by P-glycoprotein in mice.	2005-01-07	15936515
Synergism between topiramate and budipine in refractory status epilepticus in the rat.	2004-11	15509230
Antiapoptotic effects of budipine.	2004-10	15480843
Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired Long QT syndrome by antiparkinsonian drug budipine.	2003-11	14557918
Evaluation of possible pro- or antioxidative properties and of the interaction capacity with the microsomal cytochrome P450 system of different NMDA-receptor ligands and of taurine in vitro.	2003-06	12877357
[Diagnosis and treatment of Parkinson's syndrome. What is important for the general practitioner?].	2003-05-26	14579497
[Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient].	2002-05-06	12070848
Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen.	2002-05	12020263
Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.	2001-09	11554551
Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates.	2001-08	11505218
Dose linearity and steady state pharmacokinetics of the new antiparkinson agent budipine after oral administration.	2001-06	11430634
Sudden daytime sleep onset in Parkinson's disease: polysomnographic recordings.	2001-05	11391745
Non-dopaminergic drug treatment of Parkinson's disease.	2001-04	11336607
[Monotherapy of Parkinson's disease with budipine. A double blind comparison with amantadine].	2001-02	11253562
Workshop IV: drug treatment guidelines for the long-term management of Parkinson's disease.	2000-09	11199819
[Synthesis, physical-chemical properties and pharmacologically-oriented screening studies on budipine and related 4,4-diphenylpiperidines].	1984	6539602

Patents

Sample Use Guides

In Vivo Use Guide

The dosage is determined individually. The treatment should start with 3 times daily 10 mg budipine hydrochloride. If necessary, the daily dose should be increased at the earliest after 1 week to 3 x 20 mg budipine hydrochloride or 2 x 30 mg budipine hydrochloride.

Route of Administration: Oral

In Vitro Use Guide

10(-7), 10(-8), 10(-9) mol/l of budipine significantly reduced release of TNF-alpha and Il-6 in PBMC and decreased apoptotic cell death after 50 hours and 74 hours in the SH-SY 5Y cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:51 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:51 GMT 2025`
Record UNII	L9026OPI2Z
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUDIPINE [MI]

Preferred Name

English

BUDIPINE

Official Name

English

1-TERT-BUTYL-4,4-DIPHENYLPIPERIDINE

Systematic Name

English

Budipine [WHO-DD]

Common Name

English

budipine [INN]

Common Name

English

BUDIPINE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C93038